Zydus Pharmaceuticals has received FDA approval for a new generic drug, expected to significantly impact the market by providing a cost-effective alternative for patients and competitors. This regulatory milestone anticipated on June 30, 2026, is poised to bolster the company’s revenue streams and market share.